Quince Therapeutics: chief executive officer change and name change

What happened

• The filing announced that, effective Oct 8, 2026, Dirk Thye, M.D., resigned as chief executive officer, chief medical officer and as a director, and Brendan Hannah resigned as chief operating officer, chief business officer and chief compliance officer.
• The filing announced that, effective Oct 8, 2026, the board appointed Brigette Roberts, M.D., as chief executive officer; John Militello, CPA, as chief financial officer; and Keith R. Fandrick, Ph.D., as chief operating officer.
• The filing reported that on Oct 8, 2026 the company filed a certificate of amendment to change its name from Quince Therapeutics, Inc. to IRulya Therapeutics Inc., which will become effective at 4:01 p.m., Eastern Time, on Oct 9, 2026; trading is expected to move to the Nasdaq Capital Market and trade under the new symbol "IRLA" beginning with the opening of trading on Oct 12, 2026.

Key details

• Brigette Roberts will receive an annual base salary of $600,000 and a target annual bonus of 50% of her base salary; her May 18, 2026 employment letter and prior severance agreement terms are described and incorporated by reference.
• John Militello will receive an annual base salary of $440,000 and a target annual bonus of 45% of his base salary; he is eligible for a restricted stock unit award covering 80,000 shares vesting over four years and severance payments of nine months' base salary (or enhanced benefits in a change in control).
• Keith R. Fandrick will receive an annual base salary of $450,000 and a target annual bonus of 45% of his base salary; applicable prior severance terms from Orphai are described and incorporated by reference.
• The filing announced director resignations effective Oct 8, 2026 (June Bray, David Lamond, Christopher Senner and Dirk Thye) and the appointment of four new directors effective Oct 8, 2026: Catherine M. Bonuccelli, Leone Patterson, James Valentine and Drayton Wise. The board approved termination of the outside director compensation policy effective Oct 7, 2026, and the company relocated its principal executive office effective Oct 10, 2026 to 101 College Street, Suite 210, New Haven, CT 06510; telephone 203-208-8994.

Why it may matter

• Item 5.02 reports departure and election of officers and directors (officer resignations, new appointments, employment and severance arrangements). Item 5.03 reports the amendment to the certificate of incorporation changing the company name to IRulya Therapeutics Inc. Item 7.01 furnished a press release about the name and symbol change. Item 8.01 reported termination of the outside director compensation policy and the office relocation. The filing does not show why the insider traded or why the company acted.